FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
This article was originally published in The Tan Sheet
Executive Summary
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
You may also be interested in...
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains